Trader consensus on Polymarket prices an 83.5% chance of no new COVID-19 variant of concern (VOC) before 2027, driven by sustained population immunity from updated vaccines and prior infections that have blunted recent subvariants. The highly mutated BA.3.2 "Cicada" strain, detected in over 30 U.S. states and Europe since March 2026, remains classified only as a WHO variant under monitoring (VUM)—not a VOC—due to no evidence of heightened severity, hospitalizations, or deaths despite its immune evasion potential. ECDC's April 24 update confirms no VOC upgrades, with surveillance showing stable case trends amid low seasonal activity. Upcoming WHO vaccine deliberations in May could further align shots against circulating SARS-CoV-2 lineages, reinforcing this low-risk outlook.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$237,330 Vol.
$237,330 Vol.
$237,330 Vol.
$237,330 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Market Opened: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket prices an 83.5% chance of no new COVID-19 variant of concern (VOC) before 2027, driven by sustained population immunity from updated vaccines and prior infections that have blunted recent subvariants. The highly mutated BA.3.2 "Cicada" strain, detected in over 30 U.S. states and Europe since March 2026, remains classified only as a WHO variant under monitoring (VUM)—not a VOC—due to no evidence of heightened severity, hospitalizations, or deaths despite its immune evasion potential. ECDC's April 24 update confirms no VOC upgrades, with surveillance showing stable case trends amid low seasonal activity. Upcoming WHO vaccine deliberations in May could further align shots against circulating SARS-CoV-2 lineages, reinforcing this low-risk outlook.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions